Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2007

View Archived Issues

Antigenics updates pipeline progress

Recent GlaxoSmithKline patents report novel analgesic agents

Novel therapeutic option for thrombosis reported in recent Wyeth patent

Positive phase III results for rilonacept in cryopyrin-associated periodic syndromes

C1 inhibitor concentrate relieves skin swelling in hereditary angioedema

Preseasonal treatment increases grass allergen tablet efficacy

Bevacizumab active in pretreated ovarian cancer

Pfizer reports phase III data for maraviroc

Dermatrends and Teikoku Pharma to develop antipsychotic patch formulation

Sebivo approved in China for chronic hepatitis B

Aegis forms spin-out company Cedar Therapeutics

Samaritan completes acquisition of Metastatin Pharmaceuticals

Protox Therapeutics anticipates 2007 milestones

Argenta and Genentech expand drug discovery agreement

CRT and Fox Chase begin drug discovery collaboration in oncology

Gruenenthal licenses urinary incontinence product to KeyNeurotek

Extension study opens for MBP-8298 in secondary progressive MS

Novavax licenses VLP technology from U. of Massachusetts

TMC-278 meets 48-week endpoint in treatment-naive HIV patients

Bosentan meets endpoints in chronic thromboembolic pulmonary hypertension

PCSK9: a novel target for lowering LDL and preventing coronary heart disease

DPPI mediates neutrophil recruitment and inflammation in abdominal aortic aneurysms

Recent patents disclose novel agents for treating anxiety, depression, sleep disorders, etc.

Remicade receives new E.U. approval for dosing flexibilty in rheumatoid arthritis

U.S. first to approve Tekturna

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...